Climbing Ambarella Shares Could Cool Off

AMBA's near-term options are inexpensive right now

by Emma Duncan

Published on Mar 14, 2019 at 1:49 PM

GoPro (GPRO) supplier Ambarella Inc (NASDAQ:AMBA) has been climbing higher on the charts, now up 46% from its Nov. 20 four-year low of $30. However, one technical signal indicates AMBA's upside momentum could cool off in the near future.

At last glance, Ambarella stock was trading flat, just above $43.80. Digging deeper, AMBA is now trading within one standard deviation of its 80-week moving average, after a lengthy stretch below this trendline. The stock has made similar run-ups seven times in the past 15 years, shedding 6.1%, on average, one month out, per Schaeffer's Senior Quantitative Analyst Rocky White. Another plunge of this magnitude would put AMBA stock just above $41.

Weekly Chart of AMBA with 80MA

Switching to options data, AMBA traders are more call-heavy than usual right now. This is per the security's Schaeffer's put/call open interest ratio (SOIR) of 0.22, in the 12th annual percentile, suggesting near-term call open interest exceeds put open interest by a much wider-than-usual margin. Should AMBA once again retreat in the face of its 80-week trendline, an exodus of option bulls could weigh on the shares.

In closing, it may be a good time for traders to speculate on Ambarella stock's near-term trajectory with options. The tech name's Schaeffer's Volatility Index (SVI) of 38% ranks in the 2nd annual percentile, meaning short-term options are extremely cheap at the moment, from a historical volatility perspective.

a schaeffer's exclusive


Heat up your summer trading with this FREE insider report!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.
3 Drug Stocks Seeing Unusual Options Trading Today
The FDA approved Sesen's request to move manufacturing for its bladder cancer drug
BofA-Merrill Lynch: Buy This Shoe Stock Before Earnings
The brokerage firm thinks the retailer can rally another 26%
This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.